Breaking News

Takeda, Amylin End Pact

By Gil Roth | December 26, 2012

Commercial prospects sink obesity combo

Takeda Pharmaceutical Co. and Amylin Pharmaceuticals have mutually terminated their worldwide agreement to co-develop and commercialize compounds for obesity. The pact began in October 2009, .

The companies announced in August 2011 their decision to discontinue the development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity. That joint decision was based on a commercial reassessment of the pramlintide/metreleptin program, which had been in Phase II development as a twice-a-day injection formulation. The companies have since decided to formally terminate the partnership at this time. Amylin was purchased by Bristol-Myers Squibb and AstraZeneca in June 2012.

Takeda released a statement that read, "Having greatly benefited from the Amylin team's collective experience and scientific expertise, Takeda will continue to enhance its R&D activities in the area of obesity as well as its other core therapeutic areas to meet the needs of patients."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016